🇺🇸 FDA
Pipeline program

Tecentriq 1 200 mg concentrate for solution for infusion, CISPLATIN , CARBOPLATIN , BNT327, ETOPOSIDE

BNT327-03

Phase 3 small_molecule active

Quick answer

Tecentriq 1 200 mg concentrate for solution for infusion, CISPLATIN , CARBOPLATIN , BNT327, ETOPOSIDE for English First-line extensive-stage small-cell lung cancer (ES-SCLC) is a Phase 3 program (small_molecule) at BioNTech Manufacturing GmbH with 1 ClinicalTrials.gov record(s).

Program details

Company
BioNTech Manufacturing GmbH
Indication
English First-line extensive-stage small-cell lung cancer (ES-SCLC)
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials